Female Infertility Market Trends That Will Shape the Next Decade: Insights from Technological Advancements In Market With Non-Invasive Diagnostic Tests

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Female Infertility Market Size By 2025?
The valuation of the female infertility market has demonstrated consistent expansion over the past few years, projected to rise from $1.79 billion in 2024 to reach $1.86 billion in 2025, reflecting a compound annual growth rate of 4.2%; this upward trajectory during the review period is fundamentally driven by several factors, notably the escalating tendency for women to postpone motherhood, shifts in contemporary lifestyle patterns, mounting governmental supportive programs, an expanding demographic of older individuals, and a greater adoption of assisted reproductive technology procedures.

How Big Is the Female Infertility Market Size Expected to Grow by 2029?
Anticipated over the coming years is a stable expansion within the female infertility market, projected to reach a valuation of $2.18 billion by 2029, propelled by a compound annual growth rate (CAGR) of 4.0%; this upward trajectory during the forecast period is fundamentally linked to broader recognition of fertility challenges, a documented rise in conditions such as polycystic ovary* syndrome and uterine structural issues, the increasing frequency of inheritable illnesses, and escalating rates of obesity, while key shifts influencing this landscape involve progress in preimplantation genetic screening, technological evolution across the sector, the introduction of innovative diagnostic methods, greater emphasis on preserving fertility options, and the expanding use of telemedicine services.

View the full report here:
https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

Which Key Market Drivers Powering Female Infertility Market Expansion and Growth?
Anticipated expansion in the rate of infertility is projected to fuel the advancement of the female infertility market in the future. Conception proves impossible for individuals failing to get pregnant following a full year of consistent, unprotected sexual activity, a condition known as infertility. This growing incidence is attributed to several contributors, including deferred parenthood, alterations in daily habits, exposure to harmful environmental substances, escalating rates of obesity, and increased psychological tension. Interventions for female infertility become necessary to rectify and control foundational physiological, hormonal, or anatomical problems that hinder the capacity to conceive, thus improving the likelihood of pregnancy and averting long-term sterility. As an illustration reported in July 2024 by the Human Fertilization and Embryology Authority, an official UK body under the Department of Health and Social Care, UK fertility centers operating under a license completed close to 77,000 IVF cycles involving both fresh and cryopreserved embryo transfers for 52,500 patients during 2022. More than ninety percent of these individuals pursued treatment alongside a partner, encompassing roughly 100,000 people in total. Consequently, the greater frequency of infertility is the primary impetus behind the expansion witnessed in the female infertility market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Female Infertility Market?
Leading corporations within the female infertility sector are concentrating efforts on engineering groundbreaking offerings, exemplified by methods such as non-surgical diagnostic evaluations, as a means to secure greater market positioning. A diagnostic assessment that bypasses the need for surgical intervention or penetration of the body is defined as non-invasive. Illustratively, the US biotechnology firm Heranova Lifesciences initiated an early access scheme in August 2024 for their product, HerResolve, which functions as a non-invasive means to diagnose endometriosis, a condition impacting roughly 200 million females globally, manifesting through issues like sterility, discomfort, and hemorrhage. Given that the principal diagnostic approach, exploratory laparoscopic surgery, is inherently invasive and symptoms fluctuate widely, the average timeframe for affected individuals to achieve a confirmed diagnosis stretches to between seven and ten years following the initial presentation of symptoms; HerResolve presents the possibility of compressing this protracted diagnostic period from numerous years down to a matter of months, thereby fostering enhanced results for both patients and the broader healthcare system, with the ultimate goal of markedly accelerating this process for superior patient management and results.

What Are the Emerging Segments in the Female Infertility Market?
The female infertilitymarket covered in this report is segmented -

1) By Treatment: Clomiphene Citrate; Gonadotropins; Metformin; Letrozole; Bromocriptine
2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
3) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Subsegments:
1) By Clomiphene Citrate: Oral Clomiphene Citrate; Injectable Clomiphene Citrate
2) By Gonadotropins: Recombinant Gonadotropins; Urinary Gonadotropins; Human Chorionic Gonadotropin (hCG)
3) By Metformin: Immediate-Release Metformin; Extended-Release Metformin
4) By Letrozole: Oral Letrozole Tablets; Injectable Letrozole
5) By Bromocriptine: Oral Bromocriptine Tablets; Intranasal Bromocriptine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20787&type=smp

Who Are the Global Leaders in the Female Infertility Market?
Major companies operating in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd

Which are the Top Profitable Regional Markets for the Female Infertility Industry?
Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20787

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.